Johnson Lau, Chief Executive Officer, Athenex, added,“Athenex is excited to partner with Chongqing Jingdong Pharmaceutical to develop and commercializeKX2-391. Chongqing Jingdong Pharmaceutical is a pioneer in pharmaceutical drug sales and distribution in China. We are impressed by the management team of Chongqing Jingdong Pharmaceutical and are confident that this partnership will create strong synergies and a platform for growth for both companies in China. Chongqing Jingdong Pharmaceutical’s experience and execution in the Chinese market will be critical to bringing our product to market in the country.”
Athenex has a license agreement with Almirall, S.A. on the rights toKX2-391 ointment in the following territories: USA, European Union, Russia and Turkey. Details of this arrangement were disclosed in December 2017.
About Chongqing Jingdong Junzhuo Pharmaceutical Co., Ltd.
Located in Chongqing’s Liangjiang New District, the third national development and opening zone in China, Chongqing Jingdong Pharmaceutical is a fully-integrated pharmaceutical enterprise with both sales and research & development capability. It has a comprehensive product portfolio, spanning drugs, clinical products and medical devices. Chongqing Jingdong Pharmaceutical is dedicated to product and system innovation, with an ultimate goal of improving quality and efficacy of clinical studies and providing clinical products that are in high demand. Chongqing Jingdong Pharmaceutical has adopted an innovative sales and marketing model which provides drug developers and manufacturers withone-stop marketing and distribution services. Chongqing Jingdong Pharmaceutical has already established collaborative relationships with various first-tier drug R&D and manufacturing companies. In the future, Chongqing Jingdong Pharmaceutical will continue to commercialize products that treat patients with cancer, infection, hypertension or diabetes, with quality and efficacy being the top priority. For more information, please visit www.chcmedicine.com.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based onnon-absorbedP-glycoprotein inhibitor, (2) Src kinase inhibition,(3) T-cell receptor-engineeredT-cells(TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; and multiple locations in Chongqing, China. For more information, please visit www.athenex.com.
Forward-Looking Statement
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “will,” and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital to continue as a going concern; competition; intellectual property risks; risks relating to doing business in China; and the other risk
